Cargando…

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation

INTRODUCTION: Bilastine is a second-generation H(1) antihistamine indicated for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria. On the basis of the demonstrated efficacy and safety of the oral formulation, a new ophthalmic formulation of bilastine was recently developed. Pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ochoa, Dolores, Román, Manuel, Belmonte, Carmen, Martín-Vilchez, Samuel, Mejía-Abril, Gina, Abad-Santos, Francisco, Hernández, Gonzalo, Arranz, Paula, Elgezabal, Lorena, Fernández, Nieves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280016/ https://www.ncbi.nlm.nih.gov/pubmed/34125400 http://dx.doi.org/10.1007/s12325-021-01801-y

Ejemplares similares

Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study
por: Kuna, Piotr, et al.
Publicado: (2023)

Ocular Biodistribution of Once-Daily 0.6% Bilastine Eye Drops Reveals Highest Levels in Conjunctiva Up to 24 h Postadministration
por: Torrens, Inés, et al.
Publicado: (2022)

Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism
por: Mejía-Abril, Gina, et al.
Publicado: (2021)

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine
por: Calleja, Sofía, et al.
Publicado: (2023)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride
por: Villapalos-García, Gonzalo, et al.
Publicado: (2023)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen, Jie, et al.
Publicado: (2017)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
Publicado: (2018)

Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency
por: Lasseter, Kenneth C., et al.
Publicado: (2013)

Bilastine for allergic rhinoconjunctivitis, urticaria
Publicado: (2022)

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine Pharmacokinetics and Safety
por: Soria-Chacartegui, Paula, et al.
Publicado: (2023)

Experience with bilastine in the management of urticaria: Original Real-world cases of Bilastine In Treatment (ORBIT) in Asia
por: Cheong, Wai Kwong, et al.
Publicado: (2022)

Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Once– versus twice–daily tacrolimus: are the formulations equivalent?
por: Ciszek, Michał
Publicado: (2013)

Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide
por: Soria-Chacartegui, Paula, et al.
Publicado: (2023)

Polymorphism of Drug Transporters, Rather Than Metabolizing Enzymes, Conditions the Pharmacokinetics of Rasagiline
por: Zubiaur, Pablo, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects
por: Togawa, Michinori, et al.
Publicado: (2016)

Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin
por: Villapalos-García, Gonzalo, et al.
Publicado: (2021)

Bilastine: new insight into antihistamine treatment
por: Ridolo, Erminia, et al.
Publicado: (2015)

Elucidation of Inverse Agonist Activity of Bilastine
por: Mizuguchi, Hiroyuki, et al.
Publicado: (2020)

Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food
por: Lamba, Manisha, et al.
Publicado: (2016)

Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole
por: Ochoa, Dolores, et al.
Publicado: (2020)

Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria
por: Rodríguez, Mónica, et al.
Publicado: (2020)

Identification of Transporter Polymorphisms Influencing Metformin Pharmacokinetics in Healthy Volunteers
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2023)

The pharmacokinetics of once-daily dosing with gentamicin in women with postpartum endometritis.
por: Sunyecz, J A, et al.
Publicado: (1998)

Chronic non-cancer pain: Focus on once-daily tramadol formulations
por: Coluzzi, Flaminia, et al.
Publicado: (2007)

Effects of Converting Tacrolimus Formulation from Twice-Daily to Once-Daily in Liver Transplantation Recipients
por: Thorat, Ashok, et al.
Publicado: (2014)

Bioavailability of Oniria(®), a Melatonin Prolonged-Release Formulation, Versus Immediate-Release Melatonin in Healthy Volunteers
por: Román Martinez, Manuel, et al.
Publicado: (2022)

Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria
por: Sadaba, Belen, et al.
Publicado: (2013)

The safety and tolerability profile of bilastine for chronic urticaria in children
por: Papadopoulos, Nikolaos G., et al.
Publicado: (2019)

Formulation and Evaluation of Once Daily Minocycline Hydrochloride Extended Release Matrix Tablets
por: Keny, R. V., et al.
Publicado: (2009)

The Effect of Once-Daily Gabapentin Extended Release Formulation in Patients With Postamputation Pain
por: Knezevic, Nebojsa Nick, et al.
Publicado: (2019)

First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers
por: Hernández-Jiménez, Macarena, et al.
Publicado: (2022)

Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
por: deVries, Tina, et al.
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin(®) in Children and Adults
por: Papathanasiou, Theodoros, et al.
Publicado: (2021)

Comparative efficacy of bilastine, levocetirizine and desloratadine updosing in chronic urticaria
por: Staevska, Maria T
Publicado: (2016)

Effect of Bilastine on Diabetic Nephropathy in DBA2/J Mice
por: Verta, Roberta, et al.
Publicado: (2019)

A Comparative Analysis of Once-daily and Twice-daily Formulation of Tacrolimus in De Novo Kidney Transplant Recipients
por: Ferhatoglu, Murat Ferhat, et al.
Publicado: (2021)

Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation
por: Schopf, Lisa, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r42cn7hi5g3t76kuo07fe1bni4